CHIEF FINANCIAL OFFICER · Enliven Therapeutics, Inc. · Enliven Therapeutics, Inc. — Stock Option (right to buy)
Side
M
Value
—
Shares
3,982
Price
—
Executed
Sep 17, 2026
Disclosed
Sep 21, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Sep 17 executedSep 21, 2026 disclosed
ELVN · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Option exercise — administrative, little informational value
Relative size+1 / 25
No reported dollar value · 2.2% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+4 / 15
5 prior trades recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Enliven Therapeutics, Inc. — Stock Option (right to buy)
Ticker
ELVN
Shares
3,982
Price per share
$0
Execution date (reported)
Sep 17, 2026
Owned after transaction
181.0K shares
Rule 10b5-1 plan
Yes, as checked by the filer
Days from execution to publication
4
What this establishes
Hohl Benjamin filed this Form 4 reporting a option exercise of ELVN on Sep 17, 2026. It became public on Sep 21, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
CHIEF FINANCIAL OFFICER
Hohl Benjamincik:0001882764
Issuer
Enliven Therapeutics, Inc.cik:0001672619
Revision history · 0
No field has changed since this record was first ingested.
